Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MYRIAD GENETICS INCMYGN · Entity 5953 | President Crescendo BioScience | September 30, 2019 | October 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MYRIAD GENETICS INC
Report date September 30, 2019 · Filed October 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,636 |
Ending reported balance
After 2019-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-09-30 · Disposition to issuer · Disposed 6,149 · Balance 165,594 F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Row 2 · 2019-09-30 · Disposition to issuer · Disposed 4,958 · Balance 160,636 F2: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person.
F2: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2019 Filed Oct 1, 2019 22:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,958 | $28.63 | $141,947.54 |
DisclosureSEC source: 0001628656-19-000009 · edgardoc.xml · nonDerivative · entry 2 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,636 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 22:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 6,149 | $28.63 | $176,045.87 |
DisclosureSEC source: 0001628656-19-000009 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,594 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 21:12 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,958 | $29.93 | $148,392.94 |
DisclosureSEC source: 0001628656-19-000007 · edgardoc.xml · nonDerivative · entry 3 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,743 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 21:12 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,339 | $29.93 | $129,866.27 |
DisclosureSEC source: 0001628656-19-000007 · edgardoc.xml · nonDerivative · entry 2 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,701 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 21:12 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628656-19-000007 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,040 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 26, 2020, 25% on September 26, 2021, 25% on September 26, 2022, and 25% on September 26, 2023. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 20:40 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 11,712 | $40.00 | $468,480.00 |
DisclosureSEC source: 0001628656-19-000005 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,040 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 3,734 | $29.00 | $108,286.00 |
DisclosureSEC source: 0001628656-19-000002 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,752 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 13:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 6,149 | $46.00 | $282,854.00 |
DisclosureSEC source: 0001628656-18-000008 · edgardoc.xml · nonDerivative · entry 2 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,486 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 13:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,958 | $46.00 | $228,068.00 |
DisclosureSEC source: 0001628656-18-000008 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,635 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 18:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,958 | $46.65 | $231,290.70 |
DisclosureSEC source: 0001628656-18-000006 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,593 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 16:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628656-18-000004 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,551 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 25, 2019, 25% on September 25, 2020, 25% on September 25, 2021, and 25% on September 25, 2022. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 00:39 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 3,621 | $34.91 | $126,409.11 |
DisclosureSEC source: 0001628656-18-000002 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,551 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 21:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 5,218 | $36.18 | $188,787.24 |
DisclosureSEC source: 0001628656-17-000006 · edgardoc.xml · nonDerivative · entry 2 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,172 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 21:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 6,472 | $36.18 | $234,156.96 |
DisclosureSEC source: 0001628656-17-000006 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,390 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:46 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628656-17-000004 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,862 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 25, 2018, 25% on September 25, 2019, 25% on September 25, 2020, and 25% on September 25, 2021. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 18:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,631 | $16.93 | $44,542.83 |
DisclosureSEC source: 0001628656-17-000002 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,360 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 22:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 4,661 | $20.58 | $95,923.38 |
DisclosureSEC source: 0001628656-16-000008 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,991 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance stock units granted to the reporting person. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 18:03 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628656-16-000006 · edgardoc.xml · nonDerivative · entry 2 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,220 F2 · kind: Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 30, 2017, 25% on September 30, 2018, 25% on September 30, 2019, and 25% on September 30, 2020. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 18:03 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 49,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001628656-16-000006 · edgardoc.xml · nonDerivative · entry 1 Tobin Bernard · CIK 0001628656 · President Crescendo BioScience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,220 F1 · kind: Consists of performance stock units granted pursuant to the Company?s 2010 Employee, Director and Consultant Equity Incentive Plan. Each performance stock unit represents a contingent right to receive one share of the Company?s common stock,and vests 25% on September 30, 2016, 25% on September 30, 2017, 25% on September 30, 2018, and 25% on September 30, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.